In particular, the targeting of cell cycle progression has advanced greatly with the development of CDK4/6 inhibitors that are now in clinical use for HER2+ breast cancer and are under investigation for the treatment of a variety of Rb1+ cancers (Xu et al., 2017; Pesch et al., 2022). This evidence concerns the gene RB1 and cancer.